These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. LeMaistre CF; Meneghetti C; Rosenblum M; Reuben J; Parker K; Shaw J; Deisseroth A; Woodworth T; Parkinson DR Blood; 1992 May; 79(10):2547-54. PubMed ID: 1586707 [TBL] [Abstract][Full Text] [Related]
9. Protein engineering of diphtheria-toxin-related interleukin-2 fusion toxins to increase cytotoxic potency for high-affinity IL-2-receptor-bearing target cells. Kiyokawa T; Williams DP; Snider CE; Strom TB; Murphy JR Protein Eng; 1991 Apr; 4(4):463-8. PubMed ID: 1881872 [TBL] [Abstract][Full Text] [Related]
10. Interleukin 7 (IL-7) receptor-specific cell killing by DAB389 IL-7: a novel agent for the elimination of IL-7 receptor positive cells. Sweeney EB; Foss FM; Murphy JR; vanderSpek JC Bioconjug Chem; 1998; 9(2):201-7. PubMed ID: 9548535 [TBL] [Abstract][Full Text] [Related]
11. Genetic construction and characterization of the diphtheria toxin-related interleukin 15 fusion protein DAB389 sIL-15. vanderSpek JC; Sutherland J; Sampson E; Murphy JR Protein Eng; 1995 Dec; 8(12):1317-21. PubMed ID: 8869645 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of HIV-1 RNA production by the diphtheria toxin-related IL-2 fusion proteins DAB486IL-2 and DAB389IL-2. Zhang L; Waters C; Nichols J; Crumpacker C J Acquir Immune Defic Syndr (1988); 1992 Dec; 5(12):1181-7. PubMed ID: 1453329 [TBL] [Abstract][Full Text] [Related]
14. The effects of helix breaking mutations in the diphtheria toxin transmembrane domain helix layers of the fusion toxin DAB389IL-2. Hu HY; Huynh PD; Murphy JR; vanderSpek JC Protein Eng; 1998 Sep; 11(9):811-7. PubMed ID: 9796831 [TBL] [Abstract][Full Text] [Related]
15. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Liu TF; Urieto JO; Moore JE; Miller MS; Lowe AC; Thorburn A; Frankel AE Exp Hematol; 2004 Mar; 32(3):277-81. PubMed ID: 15003313 [TBL] [Abstract][Full Text] [Related]
16. DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Foss FM Clin Lymphoma; 2000 Nov; 1 Suppl 1():S27-31. PubMed ID: 11707860 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, cytotoxic properties and effects on early and late gene induction of a chimeric diphtheria toxin-leukemia-inhibitory factor protein. Negro A; Skaper SD Eur J Biochem; 1996 Oct; 241(2):507-15. PubMed ID: 8917449 [TBL] [Abstract][Full Text] [Related]
18. A recombinant fusion toxin targeted to the granulocyte-macrophage colony-stimulating factor receptor. Bendel AE; Shao Y; Davies SM; Warman B; Yang CH; Waddick KG; Uckun FM; Perentesis JP Leuk Lymphoma; 1997 Apr; 25(3-4):257-70. PubMed ID: 9168436 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Foss FM Ann N Y Acad Sci; 2001 Sep; 941():166-76. PubMed ID: 11594570 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Platanias LC; Ratain MJ; O'Brien S; Larson RA; Vardiman JW; Shaw JP; Williams SF; Baron JM; Parker K; Woodworth TG Leuk Lymphoma; 1994 Jul; 14(3-4):257-62. PubMed ID: 7950914 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]